BOSTON– Astria Therapeutics has granted stock options to two recently hired employees as part of an inducement for joining the company, the biopharmaceutical firm announced on Monday.
The stock options, totaling 62,000 shares of Astria common stock, were issued on June 2, 2025, under the company’s 2022 Inducement Stock Incentive Plan. The plan is used exclusively for awarding equity to individuals who were not previously employed by Astria. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4), which allows companies to offer equity-based incentives to new hires outside of shareholder-approved plans.
Each option has an exercise price of $4.78, equal to the closing price of Astria’s stock on the grant date. The options will vest over four years, with 25 percent vesting on the first anniversary of the employee’s start date, and the remainder vesting monthly over the following three years, provided the employees remain with the company.
Astria focuses on developing transformative therapies for allergic and immunologic diseases and continues to build its team as it advances its clinical and research programs.
